Last updated: 2026-09-09 05:05:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Rallybio Corporation (RLYB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $16.92, with a market capitalization of $89.88M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.67 to $17.57. This page covers its latest market performance, valuation, price trends and company information.
$89.88M | |
$16.97 | |
$206.24 | |
$1.76 | |
-- | |
6.75K | |
32.61K | |
-- | |
$17.57 | |
$3.67 | |
-- | |
-- |
Rallybio Corporation (RLYB) last closed at $0.00 as of 2026-09-08 23:58:00, -- from the previous close of $0.00.
During the latest regular trading session, RLYB traded between $1.76 and $206.24, with a volume of 6.75K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Rallybio Corporation (RLYB) moved from $16.76 to $16.92, representing a gain of 0.97% ($0.16).
The stock traded between $16.39 and $17.26 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 10.50 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 95.3%
RLYB is currently trading at $16.92, placing it 95.3% of the way from its 52-week low of $3.67 to its 52-week high of $17.57. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Rallybio Corporation (RLYB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.